Vomiting News and Research

RSS

Vomiting is the process the body uses to eject some or all of the contents of the stomach through the mouth.

Brisdelle receives FDA approval to treat hot flashes associated with menopause

The U.S. Food and Drug Administration today approved Brisdelle (paroxetine) to treat moderate to severe hot flashes (vasomotor symptoms) associated with menopause. Brisdelle, which contains the selective serotonin reuptake inhibitor paroxetine mesylate, is currently the only non-hormonal treatment for hot flashes approved by the FDA.

29 Jun 2013

People receiving emergency gallbladder surgery are more likely to experience complications

If you have severe pain just below the right side of your rib cage, you may have a gallbladder problem. And it is typically better to seek medical attention sooner than later.

28 Jun 2013

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

The US Food and Drug Administration has expanded the approved indication for Exelon Patch (rivastigmine transdermal system) to include the treatment of people with severe Alzheimer's disease with Exelon Patch 13.3mg/24h.

28 Jun 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Drinking excessive amounts of cola and eating honey made from the pollen of Rhododendrons can cause unusual syncope (fainting) and symptoms of arrhythmia, report two case studies presented as abstracts at the EHRA EUROPACE 2013 meeting, in Athens 23 to 26 June.

25 Jun 2013

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from a new study in which linagliptin demonstrated statistically significant reductions in blood glucose levels (HbA1c) after 12 weeks (the study's primary endpoint) in adults with type 2 diabetes (T2D) with moderate to severe renal impairment, compared with placebo. Most patients had T2D for more than ten years (76 percent) and were on insulin (86 percent).

24 Jun 2013

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

Sanofi US (EURONEXT: SAN and NYSE: SNY) announced today data that showed lixisenatide, an investigational once-daily prandial glucagon-like peptide 1 (GLP-1) receptor agonist, decreased HbA1c by reducing PPG (postprandial glucose) daytime exposure when added to standard of care which includes basal insulin with or without oral anti-diabetic agents (OADs). Lixisenatide is for the treatment of adults with type 2 diabetes mellitus.

24 Jun 2013

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Today, the U.S. Food and Drug Administration announced it has approved the use of Plan B One-Step (levonorgestrel) as a nonprescription product for all women of child-bearing potential.

21 Jun 2013

Vaccine given to newborns 60% effective against rotavirus in Ghana

Mayo Clinic and other researchers have shown that a vaccine given to newborns is at least 60 percent effective against rotavirus in Ghana. Rotavirus causes fever, vomiting and diarrhea, which in infants can cause severe dehydration.

18 Jun 2013

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Pharmacyclics, Inc. today announced the results of two separate Phase 2 studies suggesting that ibrutinib, an investigational oral Bruton's tyrosine kinase inhibitor, showed efficacy when used as a monotherapy in patients with relapsed/refractory mantle cell lymphoma or diffuse large B-cell lymphoma.

17 Jun 2013

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Amedra Pharmaceuticals LLC has announced re-launch of Adrenaclick®, a single-dose epinephrine auto-injector, for the emergency treatment of life threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Adrenaclick® will be available as a two-pack carton in both 0.15 mg and 0.30 mg strengths.

15 Jun 2013

Teva to present abstracts on AZILECT at MDS meeting

Teva Pharmaceutical Industries Ltd. announced today that a number of abstracts will be presented during the 17th Annual International Congress of Parkinson's Disease and Movement Disorders in Sydney, Australia, June 16-20, 2013, also known as the Movement Disorders Society.

15 Jun 2013

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Lineage Therapeutics Inc. has announced the US launch of its generic epinephrine injection, USP auto-injector, the authorized generic of Adrenaclick by Amedra Pharmaceuticals LLC, for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis.

15 Jun 2013

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Celgene International Sàrl, a subsidiary of Celgene Corporation today presented results from a randomized, placebo-controlled phase II trial in patients with Behçet's disease at EULAR, the European Congress of Rheumatology annual meeting in Madrid.

14 Jun 2013

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

From a clinical-based perspective, postoperative nausea and vomiting (PONV) can be characterized as an unmet global phenomenon in which anesthesia practitioners and PACU nurses worldwide are seeking more efficient clinical strategies for preventing PONV.

13 Jun 2013

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.

13 Jun 2013

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

New data from Boehringer Ingelheim’s interferon-free SOUND-C3 study were presented during the APASL Liver Week in Singapore. The Phase IIb study investigated the efficacy and safety of faldaprevir+ and deleobuvir+ (BI 207127) plus ribavirin in treatment-naïve patients with genotype-1b (GT-1b) hepatitis C virus (HCV),1 one of the most common types of HCV globally.2

13 Jun 2013

Findings link antihistamine use to adverse pregnancy outcomes

Women with a severe form of morning sickness who take antihistamines to help them sleep through their debilitating nausea are significantly more likely to experience adverse pregnancy outcomes, including low birth weight babies and premature births, a UCLA study has found.

11 Jun 2013

Taking precautions to protect health during summer

Summer is a time for enjoying warm weather, but spending time outside also increases the risk of contracting serious conditions like Lyme disease, poison ivy rashes, West Nile virus and allergic reactions to bee stings.

31 May 2013

CREON Delayed-Release Capsules now available in US for patients with EPI

AbbVie announced that a new, higher-dose capsule of CREON (pancrelipase) Delayed-Release Capsules is commercially available in the United States. The U.S. Food and Drug Administration recently approved CREON in a 36,000 lipase-unit dose to treat patients with exocrine pancreatic insufficiency due to cystic fibrosis, swelling of the pancreas that lasts a long time (chronic pancreatitis), removal of some or all of the pancreas (pancreatectomy), or other conditions.

31 May 2013

Vomiting News and Research

Further Reading

Brisdelle receives FDA approval to treat hot flashes associated with menopause

People receiving emergency gallbladder surgery are more likely to experience complications

FDA approves Novartis' Exelon Patch for treatment of severe Alzheimer's disease

Eisai submits BELVIQ NDS with Health Canada

Excessive intake of cola and honey can cause fainting and arrhythmia symptoms, shows study

Linagliptin significantly reduces blood glucose levels in T2D patients with moderate to severe renal impairment

Sanofi presents positive phase 3 data for GLP-1 receptor for type 2 diabetes

FDA approves use of Plan B One-Step pill for all women with child-bearing potential

Vaccine given to newborns 60% effective against rotavirus in Ghana

Ibrutinib monotherapy shows efficacy in patients with MCL or DLBCL

Amedra Pharmaceuticals re-launches single-dose epinephrine auto-injector, Adrenaclick

Teva to present abstracts on AZILECT at MDS meeting

Lineage Therapeutics announces US launch of generic epinephrine auto-injector

Celgene reports results from placebo-controlled phase II trial in patients with Behçet's disease

Combination of Pressure Right and antiemetic drug therapy can reduce PONV with no adverse effects

Apremilast continues to demonstrate meaningful clinical responses in patients with psoriatic arthritis

Investigational all-oral interferon-free combination from Boehringer Ingelheim achieves 95% viral cure rates in genotype-1b hepatitis C patients

Findings link antihistamine use to adverse pregnancy outcomes

Taking precautions to protect health during summer

CREON Delayed-Release Capsules now available in US for patients with EPI

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News